Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Retained Earnings (2016 - 2025)

China Pharma Holdings filings provide 16 years of Retained Earnings readings, the most recent being -$47.2 million for Q4 2025.

  • On a quarterly basis, Retained Earnings fell 7.24% to -$47.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$47.2 million, a 7.24% decrease, with the full-year FY2025 number at -$47.2 million, down 7.24% from a year prior.
  • Retained Earnings hit -$47.2 million in Q4 2025 for China Pharma Holdings, down from $11.4 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $12.5 million in Q2 2021 to a low of -$47.2 million in Q4 2025.
  • Median Retained Earnings over the past 5 years was -$33.7 million (2022), compared with a mean of -$19.2 million.
  • Biggest five-year swings in Retained Earnings: surged 135.4% in 2023 and later plummeted 484.44% in 2024.
  • China Pharma Holdings' Retained Earnings stood at -$32.2 million in 2021, then dropped by 12.32% to -$36.2 million in 2022, then surged by 131.63% to $11.5 million in 2023, then plummeted by 484.44% to -$44.0 million in 2024, then fell by 7.24% to -$47.2 million in 2025.
  • The last three reported values for Retained Earnings were -$47.2 million (Q4 2025), $11.4 million (Q3 2025), and -$45.3 million (Q2 2025) per Business Quant data.